Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Better than it felt

The quarter ended on a positive note, with the FDA granting approval to Zonegran zonisamide anti-convulsant capsules from Elan Corp. plc (ELN) as an adjunctive therapy to treat partial seizures in adults with epilepsy, and issuing an approvable letter for balsalazide disodium from Salix Pharmaceuticals Ltd. (TSE:SLX, Palo Alto, Calif.) to treat mild-to-moderate ulcerative colitis.

1Q approvals

That aside, the year end FDA housecleaning kept the first quarter thin on product

Read the full 692 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers